The Methyl Ester of 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid Reduces Endometrial Lesions Development by Modulating the NFkB and Nrf2 Pathways

Rosalba Siracusa, Ramona D’Amico, Marika Cordaro, Alessio Filippo Peritore, Tiziana Genovese, Enrico Gugliandolo, Rosalia Crupi, Daniela Impellizzeri, Salvatore Cuzzocrea, Roberta Fusco, Rosanna Di Paola
International journal of molecular sciences · 2021 · vol. 22(8) , pp. 3991 · doi:10.3390/ijms22083991 · PMID:33924360 · PMC8069675 · W3155161579
article OA: gold CC0 ⤵ 21 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

The methyl ester of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me) reduced endometriosis development in rats by activating Nrf2 and suppressing NFkB pathways, leading to decreased inflammation, oxidative stress, fibrosis, and lesion growth.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

The study tested whether the methyl ester of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me), administered to rats with induced endometriosis, modulates oxidative stress and inflammation in endometriotic explants and peritoneal fluid. CDDO-Me increased nuclear Nrf2 and upregulated the Nrf2 target antioxidant enzymes HO-1 and NQO-1, while decreasing lipid peroxidation (MDA) and restoring glutathione and superoxide dismutase activity; it also inhibited NFkB signaling by increasing cytosolic IκB-α and reducing nuclear NFkB levels, accompanied by lower peritoneal TNF-α, IL-1β, IL6, and IL2. The treatment reduced COX-2 and PGE2, shifted apoptosis markers by decreasing Bcl-2 and increasing Bax, and reduced AKT phosphorylation, MMP2, and VEGF, with smaller lesion size and reduced mast cell infiltration and fibrosis markers (α-SMA, fibronectin). A stated limitation is that the paper focuses on a rat model with explant and biochemical readouts rather than delineating clinical efficacy or long-term safety. This paper is centrally about endometriosis — it evaluates how CDDO-Me affects Nrf2/NFκB-mediated oxidative stress and inflammation to reduce endometrial lesion development in an endometriosis rat model.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a common gynecological disease. Here, we aimed to investigate the anti-fibrotic, anti-inflammatory, and anti-oxidative role of the methyl ester of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me) on endometriosis. An endometriosis rat model was constructed by intraperitoneally injecting recipient rats with an equivalent of tissue from the uterus of a donor animal. Endometriosis was allowed to develop for seven days. CDDO-Me was administered on the 7th day and for the next 7 days. On day 14, rats were sacrificed, and peritoneal fluid and endometriotic implants were collected. CDDO-Me displayed antioxidant activity by activating the Nfr2 pathway and the expression of antioxidant mediators such as NQO-1 and HO-1. Moreover, it reduced lipid peroxidation and increased glutathione (GSH) levels and superoxide dismutase (SOD) activity. CDDO-Me also showed anti-inflammatory activity by decreasing the expression of pro-inflammatory cytokines in peritoneal fluids and NFkB activation. It, in turn, reduced cyclooxygenase-2 (COX-2) expression in the endometriotic loci and prostaglandin E2 (PGE2) levels in the peritoneal fluids, leading to increased apoptosis and reduced angiogenesis. The reduced oxidative stress and pro-inflammatory microenvironment decreased implants diameter, area, and volume. In particular, CDDO-Me administration reduced the histopathological signs of endometriosis and inflammatory cells recruitment into the lesions, as shown by toluidine blue staining and myeloperoxidase (MPO) activity. CDDO-Me strongly suppressed α-SMA and fibronectin expression and collagen deposition, reducing endometriosis-associated fibrosis. In conclusion, CDDO-Me treatment resulted in a coordinated and effective suppression of endometriosis by modulating the Nrf2 and NFkB pathways.
Full text 22,624 characters · extracted from pmc-nxml · 4 sections · click to expand

Section 4

Female Sprague–Dawley rats (Envigo, Milan, Italy) were used in this research. The University of Messina Review Board for animal care (OPBA) approved the study. All animal experiments agreed with the new Italian regulations, EU regulations, and the ARRIVE guidelines. Animals were randomly divided into two groups, donor or recipient, and endometriosis was established as already described [ 47 ]. To stimulate similar estrogen levels, donor rats were intraperitoneally injected with 10 IU of pregnant mare serum gonadotropin (PMSG, R&D System RP1782725000) and euthanized 41 h later by CO 2 asphyxia. The uterus was removed and minced with scissors. Tissue from all donors was pooled, and the recipient animals were injected intraperitoneally with the equivalent of tissue from one uterus in 500 μL of PBS (ThermoFisher 10010023) along the midventral line. Endometriosis was allowed to develop for 7 days. Rats were randomized and assigned to the following groups: (1) Vehicle group: rats were subjected to experimental endometriosis as described above, and vehicle (0.1% dimethyl sulfoxide solvent (DMSO) (Merk 472301)) was intraperitoneally administered, on the 7th day and for the next 7 days. (2) CDDO-Me group: rats were subjected to experimental endometriosis as described above, and CDDO-Me (5 mg/Kg) was intraperitoneally administered, on the 7th day and for the next 7 days. (3) Sham group: rats were injected intraperitoneally with 500 μL of PBS without endometrial tissue, and vehicle (0.1% DMSO) was intraperitoneally administered, on the 7th day and for the next 7 days. Vehicle group: rats were subjected to experimental endometriosis as described above, and vehicle (0.1% dimethyl sulfoxide solvent (DMSO) (Merk 472301)) was intraperitoneally administered, on the 7th day and for the next 7 days. CDDO-Me group: rats were subjected to experimental endometriosis as described above, and CDDO-Me (5 mg/Kg) was intraperitoneally administered, on the 7th day and for the next 7 days. Sham group: rats were injected intraperitoneally with 500 μL of PBS without endometrial tissue, and vehicle (0.1% DMSO) was intraperitoneally administered, on the 7th day and for the next 7 days. The dose of CDDO-Me was based on previous experiments [ 48 , 49 ]. Rats were sacrificed 14 days after endometriosis induction [ 47 ]. Peritoneal fluid and endometriotic implants were collected. Implants were excised from both groups, measured [ 50 , 51 ], and processed for histological and biochemical studies. The levels of reduced GSH were determined in endometriosis lesions and hippocampi to evaluate the endogenous antioxidant defenses. GSH levels were determined using a microplate reader at 412 nm and expressed as ng/mg wet tissue [ 52 , 53 ]. Lipoperoxidation was estimated in endometriosis lesions and hippocampi using the thiobarbituric acid reactive substances (TBARS) test [ 54 , 55 ]. The levels of MDA were determined using a microplate reader at 535 nm and expressed as μmol/mg of swet tissue. In endometriosis lesions and hippocampi, determination of SOD activity was performed according to a previously described method [ 56 , 57 , 58 ]. SOD activity (U/μg protein) was determined using a microplate reader at 560 nm. Myeloperoxidase activity with 3,30,5,50-tetramethylbenzidine (TMB) was measured in endometriosis lesions and hippocampi as already described [ 59 , 60 ]. Absorbance was measured at 450 nm to estimate MPO activity. Peritoneal fluid was collected. VEGF, IL6, TNF-α, IL-1β, IL2, and PGE2 were determined using an ELISA kit (BioLegend, San Diego, CA, USA) [ 61 , 62 ]. For histopathological investigations, endometriosis lesions were fixed at room temperature in a buffered formaldehyde solution (10% in PBS); histological sections were stained with hematoxylin and eosin (H&E) and evaluated using a Leica DM6 microscope (Leica Microsystems SpA, Milan, Italy) equipped with a motorized stage and associated with Leica LAS X Navigator software (Leica Microsystems SpA, Milan, Italy) [ 63 ]. Histopathologic scores were evaluated as described previously [ 63 ]. Additionally, lesion volume was calculated according to the formula: V = (length × width 2 ) × 0.5 [ 64 ]. The degree of fibrosis was evaluated by the Masson trichrome staining performed according to the manufacturer’s protocol (Bio-Optica, Milan, Italy) [ 65 , 66 ]. Mast cells evaluation was performed by toluidine blue staining [ 67 ]. Immunohistochemical localization of α-SMA and fibronectin was performed in endometriosis lesions as already described [ 68 , 69 ]. The sections were incubated overnight with primary antibodies: anti-α-SMA antibody (Santa Cruz Biotechnology, CGA7) or anti-fibronectin antibody (Santa Cruz Biotechnology, sc-271098). All sections were washed with PBS and then treated as previously reported [ 70 , 71 ]. The stained sections were observed using a Leica DM6 microscope following a typical procedure [ 72 ]. The histogram profile is related to the positive pixel intensity value obtained [ 73 ]. Western blots were performed as already described [ 74 , 75 ]. Specific primary antibody: each antibody, anti-Nrf2 (Santa Cruz Biotechnology, sc-365949), anti-HO-1 (Santa Cruz Biotechnology, sc-390991), anti-NQO-1 (Santa Cruz Biotechnology, sc-32793), anti-IkB-α (Santa Cruz Biotechnology, sc-1643), anti-Nf-kb (Santa Cruz Biotechnology, sc-8008), anti-COX-2 (Santa Cruz Biotechnology, sc-376861), anti-Bcl-2 (Santa Cruz Biotechnology, sc-7382), anti-Bax (Santa Cruz Biotechnology, sc-7480), anti-MMP2 (Santa Cruz Biotechnology, sc-13594), anti- p -AKT (Abcam), anti-AKT (Abcam), was mixed in a 5% w / v of non-fat dried milk solution and incubated at 4 °C, overnight. Afterwards, blots were incubated with peroxidase-conjugated bovine anti-mouse IgG secondary antibody or peroxidase-conjugated goat anti-rabbit IgG (Jackson Immuno Research) for 1 h at room temperature. To verify the equal amounts of protein, membranes were also incubated with an antibody against β-actin (Santa Cruz Biotechnology). Signals were detected with an enhanced chemiluminescence detection system reagent (Super-Signal West Pico Chemiluminescent Substrate, Pierce). The relative expression of the protein bands was quantified by densitometry with Bio-Rad ChemiDoc XRS software and standardized to β-actin levels [ 76 ]. Images of blot signals were imported to analysis software (Image Quant TL, v2003). All values are expressed as mean ± standard error of the mean (SEM) of N observations. For in vivo studies, N represents the number of animals used. The results were analyzed by t -test, and the Kolmogorov–Smirnov test was applied to analyze the normal distribution of the data (Prism 8 for macOS version 8.2.1 (279)). A p -value of less than 0.05 was considered significant; * p < 0.05 vs. vehicle, ** p < 0.01 vs. vehicle, *** p < 0.001 vs. vehicle, # p < 0.05 vs. sham, ## p < 0.01 vs. sham, ### p < 0.001 vs. sham.

Intro

Endometriosis is a chronic pathology characterized by endometrial-like tissue located outside the uterine cavity [ 1 ]. It is associated with impaired fecundity and chronic pelvic pain [ 2 ]. The implantation and growth of endometrial cells influence the pelvic environment, damage ovarian tissues and immune function, and reduce follicular growth, leading to infertility, dysmenorrhea, and menstrual disorder [ 3 ]. The first-line therapy for endometriosis treatment suggests oral contraceptive pills or nonsteroidal anti-inflammatory drugs [ 4 ]. However, with these therapeutic approaches, many patients still display pelvic pain and lesion size increase. The mechanism underling endometriosis occurrence is not fully understood, but several studies demonstrated that it is associated with disorder of the oxidative balance and the immune system [ 5 , 6 ]. In particular, an altered expression of antioxidant and pro-oxidant enzymes has been detected in endometrial lesions [ 7 ]. In endometriotic cells, higher levels of superoxide anions, hydrogen peroxide, and malondialdehyde (MDA), a lipid peroxides index, were observed as compared to a healthy control, while catalase concentrations and superoxide dismutase activity were downregulated in endometriotic cells [ 8 ]. All these pieces of evidence suggest a declined antioxidant activity in endometriosis patients. Redox-sensitive nuclear factor erythroid 2-related (Nrf2) is involved in the transcription of endogenous antioxidant enzymes, and its activation could protect against the oxidative stress involved in endometriosis [ 9 ]. Investigations have shown that hallmarks of endometriosis include inflammation and cell apoptosis [ 10 ]. It correlates with increased numbers of mast cells and elevations of inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-2 and tumor necrosis factor (TNF)-α [ 11 , 12 ]. In the peritoneal fluid, these excessive levels of pro-inflammatory cytokines are regulated by the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) pathway that leads to a proinflammatory environment supporting the growth of endometriotic lesions [ 13 ]. In this inflammatory microenvironment, high reactive oxygen species (ROS) production manages NFkB expression and other genes encoding growth and angiogenic factors [ 14 ]. In particular, endometriosis is associated with increased cyclooxygenase-2 (COX2) expression and prostaglandin E2 (PGE2) levels, apoptosis, and pathological angiogenesis. PGE2 is involved in elevating anti-apoptotic and reducing pro-apoptotic proteins. Moreover, the COX-2–PGE2–pAKT axis, perturbated during endometriosis, leads to increased expression of MMP-2 and VEGF, involved in cellular migration, invasion, and angiogenesis [ 15 ]. Many compounds naturally synthetized in plants have been employed for disease management in Asian medicine [ 16 , 17 ]. In recent years, to increase their usefulness, synthetic derivatives of these molecules have been developed. The methyl ester of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me) (SigmaAldrich 218600534, Milan, Italy) has been originally developed for the treatment and prevention of cancer and inflammation [ 18 , 19 ]. It was described that CDDO-Me pharmacological effects are mediated by the interaction with cellular nucleophiles such as redox-sensitive sulfhydryl groups of proteins [ 20 , 21 ]. CDDO-Me behaves as an inhibitor of the NFkB and an activator of the Nrf2 pathways. Direct targets of CDDO-Me are IkB kinase (IKKβ) and Kelch-like ECH-associated protein 1 (Keap1). In fact, its molecular structure is similar to that of cyclopentenone prostaglandins, which play an important role in the resolution of inflammation, activating Nrf2 and suppressing NFkB activity [ 22 , 23 ]. The aim of this study was the investigation of the effects of CDDO-Me on oxidative stress and inflammation induced by endometriosis.

Results

In order to evaluate the effect of CCDO-Me on the oxidative balance, the Nrf2 pathway were examined. Western blot analysis revealed increased Nrf2 expression into the nucleus in tissues harvested from CDDO-Me-treated rats as compared to rats treated with vehicle ( Figure 1 A). Additionally, CDDO-Me treatment increased the expression of heme oxygenase 1 (HO-1) ( Figure 1 B) and NAD(P)H:quinone oxidoreductase-1 (NQO-1) ( Figure 1 C). Endometriotic explants from vehicle-treated rats showed elevated lipid peroxidation ( Figure 1 D) and low glutathione (GSH) levels ( Figure 1 E) and superoxide dismutase (SOD) activity ( Figure 1 F). CDDO-Me administration reduced MDA levels ( Figure 1 D) and increased GSH levels ( Figure 1 E) and SOD activity ( Figure 1 F). To test the anti-inflammatory activity of CDDO-Me administration on animals with endometriosis, the NFkB pathway was examined. Western blot analysis of endometrial explants from vehicle-treated rats showed low Ikb-α expression in the cytosol and high NFkB levels in the nucleus, while tissues harvested from CDDO-Me-administered rats showed increased Ikb-α expression in the cytosol ( Figure 2 A) and reduced NFkB levels in the nucleus ( Figure 2 B). Numerous inflammation-related mediators including TNF-α, IL-1β, IL6, and IL2 were evaluated in peritoneal fluids. Increased levels of proinflammatory cytokines were detected in samples from vehicle-treated rats, as compared to sham-treated animals. The levels of TNF-α ( Figure 2 C), IL-1β ( Figure 2 D), IL6 ( Figure 2 D), and IL2 ( Figure 2 F) in the peritoneal fluid collected from CDDO-Me-treated rats were significantly decreased. Western blot analysis conducted on endometriotic loci from vehicle-treated rats showed increased COX-2 expression ( Figure 3 A). Additionally, the peritoneal fluids from vehicle-treated rats displayed increased PGE2 levels compared to the sham-treated animals ( Figure 3 B). CDDO-Me administration reduced COX-2 and PGE2 increased expression as compared to vehicle-treated rats ( Figure 3 A,B). Up-regulated PGE2 levels lead to the inhibition of the apoptotic pathway [ 24 ]. In order to investigate the effect of CDDO-Me administration on apoptosis, Western blot analysis was conducted. Tissues collected from vehicle-treated rats showed increased B-cell lymphoma 2 (Bcl-2) ( Figure 3 C) and decreased B-cell lymphoma-associated X (Bax) ( Figure 3 D) expression. CDDO-Me induced apoptosis, reducing Bcl-2 and increasing Bax levels ( Figure 3 C,D). Several papers demonstrated the importance of a new vascular system formation in endometriosis [ 15 ]. Western blot analysis showed increased protein kinase B (AKT) phosphorylation in tissues harvested from vehicle-treated rats ( Figure 4 A), which was accompanied by increased matrix metalloproteinase-2 (MMP2) expression ( Figure 4 B) and vascular endothelial growth factor (VEGF) levels in the peritoneal fluids ( Figure 4 C). CDDO-Me administration reduced AKT phosphorylation Figure 4 A) and in turn reduced MMP2 expression ( Figure 4 B) and VEGF levels ( Figure 4 C). All animals from vehicle and CDDO-Me groups showed endometriosis implants, while sham-treated animals did not show any endometriosis lesions. The two groups did not show any different number of cysts. However, cysts diameter ( Figure 5 C), area ( Figure 5 D), and volume ( Figure 5 G) were smaller in the CDDO-Me-treated group ( Figure 5 B) compared to the vehicle-treated animals ( Figure 5 A). Histologically, endometriotic foci from vehicle-treated animals showed endometrial-type glands and stromal structure ( Figure 5 E,H). CDDO-Me administration reduced the histopathological signs of endometriosis ( Figure 5 F,H). Explants from vehicle-treated rats displayed increased mast cells recruitment ( Figure 5 I,K), while animals treated with CDDO-Me showed reduced mast cells infiltration into the lesions ( Figure 5 J,K). Additionally, CDDO-Me reduced myeloperoxidase (MPO) activity as compared to the vehicle-treated rats ( Figure 5 L). The presence of fibrosis was investigated by α-smooth muscle actin (α-SMA) and fibronectin immunolocalization and Masson’s trichrome staining. CDDO-Me administration significantly reduced the aniline blue-stained area ( Figure 6 B,C) as compared to vehicle-treated animals ( Figure 6 A,C). Immunohistochemical analysis was performed for α-SMA and fibronectin expression. Animals treated with CDDO-Me showed reduced α-SMA ( Figure 6 E,F) and fibronectin ( Figure 6 H,I) tissue expression compared to vehicle-treated rats ( Figure 6 D,F,G,I).

Discussion

Nowadays, endometriosis is described as an inflammatory and oxidative-like phenomenon. Oxidative stress, defined as an imbalance between the levels of reactive oxygen species and those of antioxidants, plays a key role in endometriosis pathogenesis, resulting in peritoneal cavity inflammatory responses. Furthermore, the unbalanced oxidative/antioxidative status is responsible for increased adhesion and growth of endometrial lesions [ 25 ]. Endometriotic cells showed upregulated endogenous oxidative stress, with alteration of the ROS detoxification pathways [ 26 ]. Thus, modulating intracellular ROS signaling and the related inflammatory peritoneal microenvironment may be a therapeutic strategy for endometriosis. Several in vivo [ 27 , 28 ] and in vitro [ 29 , 30 ] studies reported that CDDO-Me is a potent regulator of the cellular antioxidant response and an inhibitor of inflammation. In this paper, we show how CDDO-Me administration restored the oxidative and inflammatory peritoneal microenvironment during endometriosis, leading to a reduction of the lesions’ size. The Nrf2 regulatory pathway has a key role in protecting cells from oxidative stress. By controlling the transactivation of several cytoprotective genes, Nrf2 is involved in many human diseases including endometriosis. A controlled activation of Nrf2 reduces the risk of endometriosis development by scavenging ROS and preventing DNA instability. In physiological conditions, it binds to Keap1 which is responsible for Nrf2 poly-ubiquitination by the CUL3–KEAP1 E1 ubiquitin ligase complex and degradation by the proteasome [ 31 ]. Increased oxidative stress modifies the reactive thiols of KEAP1 leading to Nrf2 accumulation into the cytosol caused by its decreased affinity for the ubiquitin ligase complex. Thus, Nrf2 translocates into the nucleus, heterodimerizes with other proteins, and then binds to antioxidant response elements (ARE), leading to the expression of many cytoprotective proteins with detoxifying and antioxidant roles, such as NQO-1 and HO-1 [ 32 ]. The activity of antioxidant systems is compromised in endometriosis patients. In comparison with controls, higher MDA, NO, and ROS levels were found in eutopic endometrium biopsies and lesions. After CDDO-Me treatment, Nrf2 translocation into the nucleus was increased, and subsequently increased HO-1 and NQO-1 expression was found. Additionally, CDDO-Me reduced lipid peroxidation and restored the cellular antioxidant system by increasing glutathione peroxidase and SOD activity. ROS generation leads to enhanced NFkB translocation, resulting in elevated angiogenic and proinflammatory mediators in endometriosis patients as compared to healthy subjects [ 33 ]. NFkB is involved in many pathways modulating cell survival, proliferation, apoptosis, neo-vascularization, adhesion, and invasion. In normal conditions, inactive NFkB complexes are located into the cytoplasm. NFkB dimers form a complex with the Ikb inhibitors, so NFkB is unable to bind to DNA. In response to inflammatory stimuli, Ikb inhibitory proteins are phosphorylated and degraded, leading to the activation of the cytoplasmic NFkB [ 34 , 35 ], which translocates into the nucleus for regulating pro-inflammatory gene expression [ 36 ]. In particular, the activation of the NFkB pathway is responsible for the increased levels of IL6, TNF-α, IL-1β, and IL2 in the peritoneal fluid. These cytokines have an important role in constructing the peritoneal environment that induces endometriosis progression [ 37 , 38 ]. The expression of these pro-inflammatory mediators further promotes NFkB activation [ 39 , 40 ]. During the late secretory phase, NFkB dysfunction was observed in endometriosis patients. Ikb kinase was downregulated coincidently with the reduction of NFkB DNA binding. Well in line with these clinical data, in our experimental model, increased oxidative stress induced the activation of the NFkB pathway and the increased the levels of proinflammatory mediators in the peritoneal fluid. CDDO-Me, by inhibiting Ikb-α degradation and reducing NFkB expression into the nucleus, was able to reduce the expression of pro-inflammatory mediators in the peritoneal fluid. The activation of the NFkB pathway by ROS also promotes invasion and proliferation of endometriotic cells by the increase of COX-2 and PGE2 expression [ 14 , 41 ]. COX-2 expression is responsible for the activation of multiple transcriptional pathways. It has been demonstrated that COX-2 expression was significantly elevated in endometriosis patients as compared to the healthy individuals [ 42 ]. Additionally, COX-2-induced PGE2 is an important antiapoptotic mediator that inhibits programmed cell death, which is one of the main characteristics of endometriosis. Increased PGE2 signaling is associated with increased levels of anti-apoptotic Bcl-2 and reduced expression of pro-apoptotic Bax proteins [ 24 , 43 ]. CDDO-Me administration by reducing COX-2 expression into endometriosis lesions and PGE2 levels in peritoneal fluids induced apoptosis. The literature revealed that in endometriosis patients, PGE2 expression is also associated with upregulated angiogenesis [ 44 ]. Angiogenesis is a mechanism in which the cellular matrix, proteolytic enzymes, and cytokines interact to create a new blood vascular system that evolves from the existing one. This event has a key role in endometriosis development, due to the dependence of this pathology on the formation of a new vascular system. It has been described that PGE2 expression is involved in elevating MMP-2 and VEGF activity, inducing the AKT phosphorylation [ 15 ]. Our study showed that CDDO-Me, by reducing COX-2 expression and PGE2 levels, led to reduced AKT phosphorylation and MMP-2 and VEGF overexpression. A macroscopical analysis confirmed that CDDO-Me, by reducing oxidative stress and the inflammatory microenvironment, increasing apoptosis, and reducing vascular system formation, decreased diameter, area, and volume of the implants. Additionally, CDDO-Me reduced mast cell infiltration and neutrophil activation into the lesions. From the histological point of view, endometriosis loci are characterized by increased fibroblast-to-myofibroblast transdifferentiation (FMT) and epithelial–mesenchymal transition (EMT), resulting in augmented collagen production and cellular contractility, ultimately leading to fibrosis [ 45 , 46 ]. CDDO-Me was also able to reduce the expression of fibrotic proteins, including α-SMA, collagen and fibronectin, and leading to the decrease of fibrosis, extremely increased in ectopic endometria loci. The current research has some limitations. The employed endometriosis model was applied by transplanting normal rat uterine tissue into the abdominal cavity of another rat. It does not accurately represent the pathogenesis of human endometriosis. However, rat models have a long history of being widely used in endometriosis research and have also been validated as a model that depicts the pathology dynamics. In conclusion, our data suggest that CDDO-Me administration, by reducing oxidative stress and inflammation, would be useful for counteracting endometriosis grow and development.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis NF-E2-Related Factor 2 NF-kappa B Oleanolic Acid Signal Transduction Animals Apoptosis Apoptosis Cellular Microenvironment Cellular Microenvironment Cyclooxygenase 2 Cyclooxygenase 2 Cytokines Cytokines Endometriosis Female Fibrosis Inflammation Inflammation

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (84)

Cited by (21)

Source provenance

europepmc
last seen: 2026-06-20T06:14:18.781669+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:43.494969+00:00
License: CC0 · commercial use OK